Back to Authors

Lucey, Michael R.

https://orcid.org/0000-0002-0380-7980

Mayo Clinic

University of Wisconsin–Madison

Citations 6

AASLD AST Practice Guideline on adult liver transplantation: Candidate evaluation
Dove, Lorna , Chadha, Ryan , Lai, Jennifer C. , DiMartini, Andrea , Liapakis, AnnMarie , Parikh, Neehar D. , Firpi-Morell, Roberto , Conteh, Lanla , Fallon, Michael B. , Trotter, James F. , Sapisochin, Gonzalo, Lucey, Michael R. , Chadha, Ryan , Trotter, James , Ladner, Daniela P , Sapisochin, Gonzalo , Lucey, Michael R , Lai, Jennifer , Parikh, Neehar D , DiMartini, Andrea F. , Fallon, Michael B , Ladner, Daniela P.

Hepatology | December 17, 2025 | Volume: 83 | Issue: 6 | Pages: 1609-1645

10.1097/hep.0000000000001644 Get It

Background and Aims: Liver transplant is a specialized treatment for a spectrum of indications that use a scarce resource. Transplant is guided by principles of justice, equity, and benefit, with a constant conflict between competing interests. Organs are a national resource with a goal of equitable distribution across sites. An AASLD guideline for the evaluation and selection of appropriate candidates for transplant has been available since 2005. Methods: A multidisciplinary writing group of liver transplant experts and a librarian convened over 24 months. The writing group reviewed the literature, generated guideline recommendations, and rated the level of evidence for each recommendation based on the Oxford Center for Evidence-Based Medicine. The group categorized the strength of recommendations based on the level of evidence, risk-benefit ratio, and patient preferences. Conclusions: Liver transplant is a lifesaving procedure that should be offered to selected patients with clear indications and a reasonable prospect of benefit. The evaluation is designed to identify those in need, to outline hurdles to a successful outcome, and to develop an effective transplant plan. The goal of this document is to provide a template for this process.
Relationship between updated MELD and prognosis in alcohol-associated hepatitis: Opportunities for more efficient trial design
Al‐Karaghouli, Mustafa , Ventura‐Cots, Meritxell , Wong, Yu Jun , Genescà, Joan , Mathurin, Philippe, Shawcross, Debbie L. , Vargas, Vı́ctor , Verna, Elizabeth C. , Caballería, Joan, Shah, Vijay J., Kamath, Patrick S. , Lucey, Michael R. , García‐Tsao, Guadalupe , Mathurin, Philippe , Shawcross, Debbie Lindsay , Vargas, Victor , Ventura Cots, Meritxell , Bosques, Francisco , Brown, Robert S. , Louvet, Alexandre , Schnabl, Bernd , García–Tsao, Guadalupe , Bataller, Ramon A , Abraldeṣ, Juan G.

Hepatology Communications | July 31, 2024 | Volume: 8 | Issue: 8 | Pages: No page available

10.1097/hc9.0000000000000495 Get It

Background:Alcohol-associated hepatitis (AH) is associated with significant mortality. Model for End-Stage Liver Disease (MELD) score is used to predict short-term mortality and aid in treatment decisions. MELD is frequently updated in the course of AH. However, once the most updated MELD is known, it is uncertain if previous ones still have prognostic value, which might be relevant for transplant allocation and trial design. We aimed to investigate the predictive performance of updated MELDs in a prospectively collected cohort of patients with AH by the InTeam consortium.Methods:Three hundred seven patients (with 859 MELD values within 60 d of admission) fulfilled the inclusion criteria. The main endpoint was time to death or transplant up to 90 days. We used a joint model approach to assess the predictive value of updated MELDs.Results:Updated MELD measurements had a strong prognostic value for death/transplant (HR: 1.20, 95% CI: 1.14–1.27) (p< 0.0001). Previous MELD values did not add predictive value to the most current MELD. We also showed that MELD at day 28 (MELD28) had a significant predictive value for subsequent mortality/transplant in a landmark analysis (HR: 1.18, 95% CI: 1.12–1.23). We show that the use of an ordinal scale including death, transplant, and MELD28 as a trial outcome could substantially reduce the sample size required to demonstrate short-term benefit of an intervention.Conclusion:We show that updated MELDs during the trajectory of AH predict subsequent mortality or the need for transplant. MELD28 inclusion in an ordinal outcome (together with death or transplant) could increase the efficiency of randomized controlled trials.
Clinical, histological and molecular profiling of different stages of alcohol-related liver disease
Ventura‐Cots, Meritxell , Argemí, Josepmaria , Jones, Patricia D. , Lackner, Carolin , Hag, Mohamed El , Abraldeṣ, Juan G. , Alvarado, Edilmar, Clemente, Ana , Ravi, Samhita , Altamirano, José , Barace, Sergio , Caballería, Juan , Carvalhana, Sofia , Cortez‐Pinto, Helena , Costa, Adília, Degré, Delphine, Fernández‐Carrillo, Carlos , García–Tsao, Guadalupe , Koskinas, John , Lanthier, Nicolas , Lozano, Juan José , Lucey, Michael R. , Masson, Steven , Mathurin, Philippe, Miquel, Rosa , Moreno, Christophe , Mounajjed, Taofic, Sancho‐Bru, Pau , Sands, R. Warren , Szafranska, Justyna , Verset, Laurine , Schnabl, Bern, Shah, Vijay H. , Shawcross, Debbie L. , Verna, Elizabeth C. , Vargas, Vı́ctor , Woosley, John T. , Mueller, Sebastian , Stärkel, Peter , Mathurin, Philippe , Alboraie, Mohamed , Bosques, Francisco , Lanthier, Nicolas , Louvet, Alexandre , Masson, Steven , Mathurin, Philippe , Sancho-Bru, Pau , Shah, Vijay, Shawcross, Debbie Lindsay , Bataller, Ramon A , Cortez-Pinto, Helena , Vargas, Victor , Ventura Cots, Meritxell , Abraldes, Juan G , Alves, António , Brown, Robert S. , Cabezas, Joaquín , Ganne‐Carrié, Nathalie , Genescà, Joan , Louvet, Alexandre , Méndez‐Sánchez, Nahúm , Òdena, Gemma , Kim, Won Kyum , Schnabl, Bernd , Sempoux, Christine , Stauber, Rudolf E , Straub, Beate Katharina , Tiniakos, Dina , Trépo, Eric , Villanueva, Càndid , Ziol, Marianne

Gut | January 6, 2022 | Volume: 71 | Issue: 9 | Pages: 1856-1866

10.1136/gutjnl-2021-324295 Get It

Objective Alcohol-related liver disease (ALD) ranges from never-decompensated ALD (ndALD) to the life-threatening decompensated phenotype, known as alcohol-related hepatitis (AH). A multidimensional study of the clinical, histological and molecular features of these subtypes is lacking. Design Two large cohorts of patients were recruited in an international, observational multicentre study: a retrospective cohort of patients with ndALD (n=110) and a prospective cohort of patients with AH (n=225). Clinical, analytical, immunohistochemistry and hepatic RNA microarray analysis of both disease phenotypes were performed. Results Age and mean alcohol intake were similar in both groups. AH patients had greater aspartate amino transferase/alanine amino transferase ratio and lower gamma-glutamyl transferase levels than in ndALD patients. Patients with AH demonstrated profound liver failure and increased mortality. One-year mortality was 10% in ndALD and 50% in AH. Histologically, steatosis grade, ballooning and pericellular fibrosis were similar in both groups, while advanced fibrosis, Mallory-Denk bodies, bilirubinostasis, severe neutrophil infiltration and ductular reaction were more frequent among AH patients. Transcriptome analysis revealed a profound gene dysregulation within both phenotypes when compare to controls. While ndALD was characterised by deregulated expression of genes involved in matrisome and immune response, the development of AH resulted in a marked deregulation of genes involved in hepatocyte reprogramming and bile acid metabolism. Conclusions Despite comparable alcohol intake, AH patients presented with worse liver function compared with ndALD patients. Bilirubinostasis, severe fibrosis and ductular reaction were prominent features of AH. AH patients exhibited a more profound deregulation of gene expression compared with ndALD patients.
The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study
Morales‐Arráez, Dalia , Ventura‐Cots, Meritxell , Altamirano, José , Abraldeṣ, Juan G. , Cruz‐Lemini, M. , Thursz, Mark , Chavez-Araujo, Roberta, Tijera, Fatima Higuera‐de la , Shah, Vijay H. , Kamath, Patrick S. , Duarte‐Rojo, Andrés , Charles, Emmanuelle, Vargas, Vı́ctor , Jäger, Marion , Rautou, Pierre‐Emmanuel , Zamarripa, Felipe , Restrepo-Gutiérrez, J.C., Torre, Aldo , Lucey, Michael R. , Mathurin, P., García–Tsao, Guadalupe , Verna, Elizabeth C. , Argemí, Josepmaria , Fernández‐Carrillo, Carlos , Clemente, Ana , Alvarado‐Tápias, Edilmar , Forrest, Ewan , Mathurin, Philippe , Duarte-Rojo, Andres , Vargas, Victor , Ventura Cots, Meritxell , Abraldes, Juan G , Rautou, Pierre-Emmanuel , Atkinson, Stephen R. , Sarin, Shiv Kumar , Kim, Won Kyum , Singal, Ashwani K. , Rincón, Diego , Arab, Juan Pablo , Louvet, Alexandre , González, José Alberto , Brown, Robert S. , Allison, Michael , Bataller, Ramon A

American Journal of Gastroenterology | December 28, 2021 | Volume: 117 | Issue: 2 | Pages: 301-310

10.14309/ajg.0000000000001596 Get It

INTRODUCTION: Several scoring systems predict mortality in alcohol-associated hepatitis (AH), including the Maddrey discriminant function (mDF) and model for end-stage liver disease (MELD) score developed in the United States, Glasgow alcoholic hepatitis score in the United Kingdom, and age, bilirubin, international normalized ratio, and creatinine score in Spain. To date, no global studies have examined the utility of these scores, nor has the MELD-sodium been evaluated for outcome prediction in AH. In this study, we assessed the accuracy of different scores to predict short-term mortality in AH and investigated additional factors to improve mortality prediction. METHODS: Patients admitted to hospital with a definite or probable AH were recruited by 85 tertiary centers in 11 countries and across 3 continents. Baseline demographic and laboratory variables were obtained. The primary outcome was all-cause mortality at 28 and 90 days. RESULTS: In total, 3,101 patients were eligible for inclusion. After exclusions (n = 520), 2,581 patients were enrolled (74.4% male, median age 48 years, interquartile range 40.9–55.0 years). The median MELD score was 23.5 (interquartile range 20.5–27.8). Mortality at 28 and 90 days was 20% and 30.9%, respectively. The area under the receiver operating characteristic curve for 28-day mortality ranged from 0.776 for MELD-sodium to 0.701 for mDF, and for 90-day mortality, it ranged from 0.773 for MELD to 0.709 for mDF. The area under the receiver operating characteristic curve for mDF to predict death was significantly lower than all other scores. Age added to MELD obtained only a small improvement of AUC. DISCUSSION: These results suggest that the mDF score should no longer be used to assess AH's prognosis. The MELD score has the best performance in predicting short-term mortality.
Proceedings from the 2018 Canadian Association for the Study of the Liver Single Topic Conference—Decompensated cirrhosis: from clinic to transplant
Dong, Victor , Gosselin, Maxime, Jagarlamudi, Nishita, Kok, Beverley, Swain, Mark G. , Bajaj, Jasmohan S. , Marquez, Vladimir , Stravitz, R. Todd , Merli, Manuela , Wong, Phil, Brisebois, Amanda, Wendon, Julia, Nyberg, Scott L. , Carrier, François Martin , Lucey, Michael R. , Rose, Christopher F. , Bissonnette, Julien , Gosselin, Maxime, Abraldeṣ, Juan G. , Montaño‐Loza, Aldo J. , Tandon, Puneeta , Wong, Florence , Feld, Jordan J. , Karvellas, Constantine

Canadian Liver Journal | December 10, 2019 | Volume: 2 | Issue: 4 | Pages: 137-170

10.3138/canlivj.2019-0011 Get It